2007
Serum Reactivity against Borrelia burgdorferi OspA in Patients with Rheumatoid Arthritis▿
Hsieh YF, Liu HW, Hsu TC, Wei J, Shih CM, Krause PJ, Tsay GJ. Serum Reactivity against Borrelia burgdorferi OspA in Patients with Rheumatoid Arthritis▿. MSphere 2007, 14: 1437-1441. PMID: 17881508, PMCID: PMC2168181, DOI: 10.1128/cvi.00151-07.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntibodies, BacterialAntigens, BacterialAntigens, SurfaceArthritis, RheumatoidAutoimmune DiseasesBacterial Outer Membrane ProteinsBacterial VaccinesBlotting, WesternBorrelia burgdorferiEnzyme-Linked Immunosorbent AssayFemaleHumansLipoproteinsLyme DiseaseMaleMiddle AgedRecombinant Fusion ProteinsConceptsRheumatoid arthritis patientsRheumatoid arthritisOspA antigenArthritis patientsAutoimmune diseasesSerum reactivityLyme diseaseDisease Activity ScoreCommon clinical featuresLyme disease patientsSurface protein AArthritis correlatesSynovial histologyOuter surface protein ALyme arthritisActivity scoreClinical featuresDisease patientsSerum concentrationsSimilar pathogenesisHealthy subjectsPatientsArthritisDisease severityDisease
2001
Safety and Immunogenicity of a Recombinant Borrelia burgdorferi Outer Surface Protein A Vaccine Against Lyme Disease in Healthy Children and Adolescents: A Randomized Controlled Trial
Sikand V, Halsey N, Krause P, Sood S, Geller R, Van Hoecke C, Buscarino C, Parenti D. Safety and Immunogenicity of a Recombinant Borrelia burgdorferi Outer Surface Protein A Vaccine Against Lyme Disease in Healthy Children and Adolescents: A Randomized Controlled Trial. Pediatrics 2001, 108: 123-128. PMID: 11433064, DOI: 10.1542/peds.108.1.123.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAntigens, SurfaceArthralgiaBacterial Outer Membrane ProteinsBacterial VaccinesBorrelia burgdorferi GroupChildChild, PreschoolEdemaErythemaExanthemaFatigueFemaleFeverHeadacheHumansImmunoglobulin GIncidenceInjectionsLipoproteinsLyme DiseaseLyme Disease VaccinesMalePainSeverity of Illness IndexTime FactorsUnited StatesConceptsLocal injection site reactionsInjection site reactionsYears of ageMonth 13LD vaccineVaccine recipientsSite reactionsHealthy childrenEfficacy studiesChildren 4Placebo-controlled clinical trialUnsolicited adverse eventsFlu-like symptomsLyme disease vaccineHigher immune responseLyme endemic areasOuter Surface ProteinsAdolescents 15 yearsIgG GMTPlacebo recipientsReactogenicity dataAdverse eventsControlled TrialsMonth 6Immunogenicity data